Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc. on February 19, 2026. The report serves as a Regulation FD disclosure regarding a press release issued on the same date. The Company is a biopharmaceutical entity focused on developing antiviral therapies, specifically highlighting its candidate CDI-988.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific corporate event rather than a periodic financial statement.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary material event is the announcement of upcoming scientific data presentation.
Guidance, Outlook, and Management Commentary
- Scientific Presentation: The Company announced that its first oral norovirus protease inhibitor, CDI-988, will be featured at the International Society for Antiviral Research Conference (ICAR) 2026.
- Event Details: The conference is scheduled to be held from April 27 to May 1, 2026, in Prague, Czech Republic.
- Legal Disclaimer: The information contained in this Item 7.01 and the accompanying press release (Exhibit 99.1) is not deemed "filed" under the Securities Exchange Act of 1934 and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific data and results to be presented for CDI-988 at the ICAR 2026 conference.
- Review the full text of the press release furnished as Exhibit 99.1 for detailed clinical context.
- Confirm the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the development timeline of CDI-988 following the conference.